Provides Update on ACTIV-4 Host Tissue Trial
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 /PRNewswire/ Rigel Pharmaceuticals, Inc. today announced an upcoming oral presentation highlighting.
/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2022, including sales of.
Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced top-line efficacy and safety results from the FOCUS Phase 3 clinical trial of.